# US 2018/0021349 A1 · Emulsion formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021349 A1
- Document ID: US20180021349A1
- Status: Published application
- Kind: A1
- Application number: 15/699,872
- Filed: 2017-10-17
- Published: 2018-01-25
- Earliest claimed: 2013-03-15
- Assignees: Marius Pharmaceuticals LLC
- Applicants: Marius Pharmaceuticals LLC
- Inventors: Om DHINGRA; James S. Bernstein
- Web page: https://patentgrep.com/patent/US20180021349A1

## CPC

- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 9/4875: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/4858)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a) from 2.5 to 37.5% by weight of solubilized testosterone undecanoate; and
b) from 2 to 65% by weight of one or more phytosterol esters,
wherein the composition is a self-emulsifying oral formulation.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, comprising from about 5% to about 37.5% by weight of one or more phytosterol esters.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, comprising from about 10% to about 37.5% by weight of one or more phytosterol esters.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, comprising from about 10% to about 25% by weight of one or more phytosterol esters.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, comprising:
a) from 2.5 to 37.5% by weight of solubilized testosterone undecanoate;
b) from 5 to 37.5% by weight of a hydrophilic surfactant;
c) from 15 to 65% by weight of a lipophilic surfactant;
d) from 5 to 37.5% by weight of one or more phytosterol esters;
e) from 0 to 15% by weight of a solubilizer; and
f) from 0 to 15% by weight of a digestible oil,
wherein the composition is a self-emulsifying oral formulation.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, comprising from 10 to 37.5% by weight of solubilized testosterone undecanoate.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the hydrophilic surfactant is selected from polyoxyethylene sorbitan fatty acid esters, hydrogenated castor oil ethoxylates, PEG mono- and di-esters of palmitic and stearic acids, fatty acid ethoxylates, and combinations thereof.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein the lipophilic surfactant is a fatty acid selected from octanoic acid, decanoic acid, undecanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, and linolenic acid.

### Claim 9 (depends on 6)

The pharmaceutical composition of claim 6, wherein the solubilizer comprises dl-alpha-tocopherol.

### Claim 10 (depends on 6)

The pharmaceutical composition of claim 6, wherein the digestible oil is a vegetable oil selected from soybean oil, safflower seed oil, corn oil, olive oil, castor oil, cottonseed oil, arachis oil, sunflower seed oil, coconut oil, palm oil, rapeseed oil, evening primrose oil, grape seed oil, wheat germ oil, sesame oil, avocado oil, almond oil, borage oil, peppermint oil and apricot kernel oil.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, comprising:
a) from 10 to 25% by weight of solubilized testosterone undecanoate;
b) from 10 to 37.5% by weight of hydrogenated castor oil ethoxylate;
c) from 10 to 60% by weight of a hydrophobic surfactant;
d) from 5 to 37.5% by weight of one or more phytosterol esters; and
e) 0-10% by weight of dl-alpha-tocopherol,
wherein the composition is a self-emulsifying oral formulation.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the hydrogenated castor oil ethoxylate is selected from Cremophor RH40 and Cremophor EL-35.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the hydrophobic surfactant is selected from Maisine 35-1, oleic acid, Imwitor 742, Lauroglycol 90, and combinations thereof.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, comprising:
a) from 10 to 25% by weight of solubilized testosterone undecanoate;
b) from 5 to 20% by weight of hydrogenated castor oil ethoxylate;
c) from 10 to 45% by weight of a hydrophobic surfactant;
d) from 5 to 45% by weight of one or more phytosterol esters; and
e) from 0 to 5% by weight of dl-alpha-tocopherol,
wherein the composition is a self-emulsifying oral formulation.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, comprising:
a) from 15 to 20% by weight of solubilized testosterone undecanoate;
b) from 10 to 20% by weight of hydrogenated castor oil ethoxylate;
c) from 35 to 45% by weight of a hydrophobic surfactant;
d) from 20 to 30% by weight of one or more phytosterol esters; and
e) from 0 to 5% by weight of dl-alpha-tocopherol,
wherein the composition is a self-emulsifying oral formulation.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the hydrogenated castor oil ethoxylate is selected from Cremophor RH40 and Cremophor EL-35.

### Claim 17 (depends on 15)

The pharmaceutical composition of claim 15, wherein the hydrophobic surfactant is selected from Maisine 35-1, oleic acid, Imwitor 742, Lauroglycol 90, and combinations thereof.

### Claim 18 (depends on 15)

The pharmaceutical composition of claim 15, comprising:
a) about 18.2% by weight of solubilized testosterone undecanoate;
b) about 15.0% by weight of Cremophor RH40;
c) about 39.9% by weight of Lauroglycol 90;
d) about 25.0% by weight of one or more phytosterol esters; and
e) about 2.0% by weight of dl-alpha-tocopherol,
wherein the composition is a self-emulsifying oral formulation.

### Claim 19 (depends on 1)

A method of treating testosterone deficiency in a subject in need thereof, said method comprising administering to the subject a pharmaceutical composition of claim 1 in an amount effective to treat the testosterone deficiency.

### Claim 20 (depends on 19)

The method of claim 19, wherein said subject is a hypogonadal male.

### Claim 21 (depends on 1)

A method of treating androgen deficiency in a subject in need thereof, said method comprising administering to the subject a pharmaceutical composition of claim 1 in an amount effective to treat the androgen deficiency.

### Claim 22 (depends on 21)

The method of claim 21, wherein said subject is a postmenopausal woman, menopausal woman, sexually dysfunctional woman, andropausal man, hypogonadal man, erectile dysfunctional man, or hypogonadal adolescent boy.
